KBC Group NV Reduces Stock Position in ICU Medical, Inc. (NASDAQ:ICUI)

KBC Group NV reduced its holdings in ICU Medical, Inc. (NASDAQ:ICUI) by 93.5% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,131 shares of the medical instruments supplier’s stock after selling 16,172 shares during the period. KBC Group NV’s holdings in ICU Medical were worth $157,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Norges Bank bought a new stake in ICU Medical during the fourth quarter worth approximately $40,151,000. GAMMA Investing LLC grew its stake in shares of ICU Medical by 17,559.7% during the first quarter. GAMMA Investing LLC now owns 99,424 shares of the medical instruments supplier’s stock valued at $138,060,000 after buying an additional 98,861 shares during the last quarter. Point72 Asset Management L.P. grew its stake in shares of ICU Medical by 63.2% during the fourth quarter. Point72 Asset Management L.P. now owns 245,340 shares of the medical instruments supplier’s stock valued at $38,069,000 after buying an additional 95,030 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of ICU Medical by 18.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 539,981 shares of the medical instruments supplier’s stock valued at $83,788,000 after buying an additional 82,982 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of ICU Medical during the fourth quarter valued at approximately $10,003,000. 96.10% of the stock is owned by hedge funds and other institutional investors.

ICU Medical Stock Performance

Shares of ICUI opened at $135.50 on Monday. ICU Medical, Inc. has a 12 month low of $117.92 and a 12 month high of $196.26. The stock has a fifty day moving average price of $134.12 and a 200-day moving average price of $145.63. The company has a current ratio of 2.59, a quick ratio of 1.52 and a debt-to-equity ratio of 0.75. The firm has a market cap of $3.33 billion, a PE ratio of -35.38 and a beta of 0.87.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.72 EPS for the quarter, beating the consensus estimate of $1.23 by $0.49. ICU Medical had a positive return on equity of 6.75% and a negative net margin of 3.87%. The firm had revenue of $599.49 million during the quarter, compared to analyst estimates of $574.15 million. During the same quarter in the prior year, the business posted $0.96 EPS. The business’s revenue for the quarter was up 6.7% compared to the same quarter last year. Equities research analysts predict that ICU Medical, Inc. will post 4.11 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Ben Sousa sold 2,000 shares of the company’s stock in a transaction on Thursday, May 15th. The stock was sold at an average price of $137.36, for a total value of $274,720.00. Following the transaction, the insider directly owned 479 shares of the company’s stock, valued at $65,795.44. This represents a 80.68% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Christian B. Voigtlander sold 4,985 shares of the company’s stock in a transaction on Wednesday, May 28th. The shares were sold at an average price of $128.50, for a total value of $640,572.50. Following the completion of the transaction, the chief operating officer directly owned 6,088 shares in the company, valued at approximately $782,308. The trade was a 45.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 36,097 shares of company stock worth $4,860,156. 1.50% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

ICUI has been the topic of a number of analyst reports. Wall Street Zen raised ICU Medical from a “hold” rating to a “buy” rating in a research note on Sunday, May 18th. KeyCorp dropped their price objective on ICU Medical from $209.00 to $191.00 and set an “overweight” rating on the stock in a research note on Monday, April 21st. Raymond James Financial lowered their target price on ICU Medical from $197.00 to $187.00 and set a “strong-buy” rating for the company in a report on Friday, May 9th. Finally, Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a report on Tuesday, April 8th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $192.67.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.